In the pivotal SOLO1 trial, olaparib demonstrated a durable progression-free survival (PFS) benefit beyond the end of treatment in patients with advanced ovarian cancer and BRCA1/2 mutations [3]. The gene discussed is BRCA1; the disease is ovarian carcinoma.